PRYTEK
23.7.2021 03:02:11 CEST | Business Wire | Press release
Aligned with Prytek’s strategy on building technologies and delivering managed services, it is building a new software testing arm by merging its own Technological company prooV™ with QAssure, a leading Asia based software testing company. After the merger Prytek will be the major shareholder providing software testing and prooV™ of Concept as a Service to the global market. Prytek is leading with the concept of BOPaaS (Business Operating Platform as Service) where it is lifting out entire operations from corporates providing them an entire operational solution based on Prytek technologies. The group operated in several sectors such as Financial Services, Cyber & Tech Education and HR sectors. This concept helps CEOs focus on their core business and outsource all banking regulations, software, and education requirements to Prytek.
QAssure and prooV™ announced their agreement to merge under the name of QAssure with Durairaj Dhanasekaran as its CEO. QAssure market-leading testing company head quartered in Singapore with a continuous testing technology platform and managed service capability. prooV™ owned by Prytek, is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. The combined services represent the most modern platform for accelerating open innovation and transforming software testing to keep pace with digital transformation. The combined entity will have a global presence with offices in Asia, the US, and EMEA. This integration will reflect the commitment to innovation and customer success that both companies share.
Andrey Yashunsky CEO of Prytek says “With this merger, we are creating deep tech proof of concept and digital assurance platform company that help accelerate and fast-track open innovation. With a strong implementation support centre based in Singapore, an R&D team based out of Israel and an offshore development team based out of India, we will be able to bring the best minds to build and deliver great technology and services addressing the global customer needs.”
Toby Olshanetsky, CEO and co-founder of prooV™ adds "We are very excited with this merger, in prooV™ we created the first PoC as a Service platform and now we create the first full end to end solution for technology & innovation adoption, using prooV™ and QAssure we provide a 360 offering: before, during and after the POC, enterprises can assess and test multiple technologies simultaneously to identify feature sets, scaling challenges, performance bottlenecks, and security risks before releasing an application to production".
According to Technavio, the global software testing services market has the potential to grow by USD 34.49 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 12.39%. Enterprises have started focusing more on Quality Assurance, which can be gained by the implementation of agile solutions, leading to significant investments for the advancement of the latest quality assurance & software testing services.
About QAssure:
QAssure Technologies is an Independent Software Testing Company founded in 2005. Headquartered in Singapore with an expanding presence in India, Malaysia, Indonesia and the USA, QAssure Technologies focuses on specialized QA Engineering and Testing services with continuous autonomous validation and verification platform. QAssure Technologies brings together the essential combinations of value-driven robust domain knowledge, platforms and exceptional technical capabilities and burgeoning strategic alliances for leading IT solutions. Our expanding global footprint makes it possible for us to meet the software testing demands with versatile delivery models and specialized resources.
About Proov:
prooV™ is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. prooV consolidates the PoC process into one end-to-end ecosystem. With its simplified configuration and single point of integration, prooV enables companies to complete PoCs within days, not months, to run multiple PoCs simultaneously and to quickly evaluate different technology solutions from pre-screened vendors. prooV is the must-have solution for any organization looking to fast-track innovation.
About Prytek:
Prytek is a multinational technology group that builds deep technology and SaaS solutions through a BOPaaS (Business Operating Platform-as-a-Service) which is a combination of Deep Tech Solutions with Managed Services and Capital, providing the capability to lift out entire operations to create more efficient businesses of the future. Headed by industry experts, Prytek builds businesses and ecosystems in the Financial Services, Cyber & Tech Education and HR sectors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005855/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom